A mounting body of evidence supports the notion that complement activation in TME significantly contributes to the advancement of tumor progression, prompting us to propose that targeting anaphylatoxin C3a and C5a signaling pathways may improve cancer immunotherapy. The gene discussed is C3; the disease is cancer.